This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rusk, A. Articles by Khanna, C. Search for Related Content PubMed PubMed Citation Articles by Rusk, A. Articles by Khanna, C.

Preclinical Evaluation of Antiangiogenic Thrombospondin-1 Peptide Mimetics, ABT-526 and ABT-510, in Companion Dogs with Naturally Occurring Cancers

Authors' Affiliations: ¹ Animal Clinical Investigation, LLC, Columbia, Maryland and ² Abbott Laboratories, Abbott Park, Illinois

Requests for reprints: Anthony Rusk, Animal Clinical Investigation, LLC, at Friendship Hospital for Animals, 4105 Brandywine St., NW, Washington, DC 20016. Phone: 410-419-0804; Fax: 202-363-7126; E-mail: trusk{at}animalci.com.

Purpose: The angiogenic phenotype of malignant cancers has been established as a target for cancer therapy. ABT-526 and ABT-510, two peptide mimetics of thrombospondin-1 (TSP-1), block angiogenesis in vitro and in vivo and slow tumor growth in mice. To guide the clinical development of these drugs, translational studies in dogs with naturally occurring cancers were initiated.

Experimental Design: A prospective open-label trial using ABT-510 or ABT-526 in pet dogs with measurable malignant spontaneously arising tumors. Endpoints included safety, pharmacokinetics, antitumor activity, and preliminary assessment of changes in circulating endothelial cell populations.

Results: Two-hundred and forty-two dogs were sequentially entered to this open-label trial. The elimination half-life for ABT-510 and ABT-526 was 0.7 and 0.8 h, respectively (range, 0.5-1 h). No dose-limiting toxicities were seen in any dogs (N = 242). Forty-two dogs receiving peptide had objective responses (>50% reduction in tumor size; n = 6) or significant disease stabilization. Most objective responses were seen after 60 days of exposure to the TSP-1 peptide. Antitumor activity was similar for both peptides and was seen in several histologies, including mammary carcinoma, head and neck carcinoma, soft tissue sarcoma, cutaneous T-cell lymphoma, and non–Hodgkin's lymphoma. Assessment of circulating endothelial cell populations in a small subset of dogs suggested that effective exposure to TSP-1 peptides may be associated with reductions in circulating endothelial cells.

Conclusions: These results support the safety and activity of ABT-526 and ABT-510 in dogs with naturally occurring malignant cancers. Data from this preclinical trial support the development of TSP-1 mimetic peptides as anticancer agents.

This article has been cited by other articles:

				R. Hasina, L. E. Martin, K. Kasza, C. L. Jones, A. Jalil, and M. W. Lingen ABT-510 Is an Effective Chemopreventive Agent in the Mouse 4-Nitroquinoline 1-Oxide Model of Oral Carcinogenesis Cancer Prevention Research, April 1, 2009; 2(4): 385 - 393. [Abstract] [Full Text] [PDF]

				B. Kaur, S. M. Cork, E. M. Sandberg, N. S. Devi, Z. Zhang, P. A. Klenotic, M. Febbraio, H. Shim, H. Mao, C. Tucker-Burden, et al. Vasculostatin Inhibits Intracranial Glioma Growth and Negatively Regulates In vivo Angiogenesis through a CD36-Dependent Mechanism Cancer Res., February 1, 2009; 69(3): 1212 - 1220. [Abstract] [Full Text] [PDF]

				J. Greenaway, J. Henkin, J. Lawler, R. Moorehead, and J. Petrik ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer Mol. Cancer Ther., January 1, 2009; 8(1): 64 - 74. [Abstract] [Full Text] [PDF]

				G. S. Butler, R. A. Dean, E. M. Tam, and C. M. Overall Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding Mol. Cell. Biol., August 1, 2008; 28(15): 4896 - 4914. [Abstract] [Full Text] [PDF]